DE-QPS/SCANTOX
30.11.2023 14:16:35 CET | Business Wire | Press release
Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO. QPS Neuropharmacology, based in Grambach, Austria and focused on drug discovery, specializes in neurodegenerative diseases, rare diseases and mental disorders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130940694/en/
QPS Neuropharmacology facility in Grambach, Austria. (Graphic: Business Wire)
Founded in 1999, QPS Neuropharmacology has built a strong global reputation for high quality services that are deeply scientifically rooted and has an undisputed track-record of serving a loyal and broad customer base globally. This long history of developing expertise within neuropharmacology preclinical studies has contributed to strong year-on-year growth and positioned the organization as a desirable acquisition target. QPS Neuropharmacology is based in a 2,700 m2 state-of-the-art facility in Grambach, Austria, and employs more than 80 employees. With on-site availability of validated transgenic and non-transgenic in-vitro and in-vivo models, QPS Neuropharmacology addresses multiple targets within the growing CNS area and represents a unique partner for biotech and pharma companies in their drug development process.
After the sale is complete, QPS will retain the European clinical division including the service capbilities in Austria, The Czech Republic, and Croatia where QPS has a long history of conducting late-phase clinical trials in neurodegenerative diseases, oncology and various rare diseases. This late-phase clinical capability will remain fully integrated with the QPS global clinical operational services organization, providing comprehensive global CRO services to pharmaceutical and biotech clients worldwide.
“The sale of QPS Neuropharmacology is a natural transition in the development of QPS as a full-service, global CRO focused on preclinical, bioanalysis and clinical research operational services. We believe that the neuropharmacology unit will be strengthened and continue to grow as part of the Scantox organization” says Ben Chien, President and CEO of QPS Holdings, LLC.
Manuela Prokesch, Director of QPS Neuropharmacology, continues: “This is a unique opportunity for us to bring our deep Neuropharmacology expertise to join a preclinical market leader, known for their high quality and customer-centric approach. We are looking forward to continuing to deliver our signature high-quality solutions to our clients while leveraging the synergies we can generate across the Scantox organization”.
QPS Neuropharmacology will continue to serve its valued clients as part of the Scantox organization. The combined company will have more than 300 employees across six sites offering lead optimization, neuropharmacology research services, regulatory toxicology and CMC/analytical services.
Advisors
Perella Weinberg Partners is serving as financial advisor to QPS Holdings, KPMG is serving as its tax advisor and Ropes & Gray together with Wolf Theiss are serving as its legal counsel. Lincoln International is serving as corporate finance advisor to Scantox, EY is serving as its financial and tax advisor, L.E.K. Consulting as its commercial advisor and Accura together with DORDA are serving as its legal counsel.
About QPS Holdings, LLC:
QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe, India and Asia. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
About Scantox:
Scantox is the leading Nordic pre-clinical GLP-accredited CRO, focused on pharmacology and regulatory toxicology, headquartered in Denmark with three subsidiaries in Sweden and one in Denmark. Based on decades of experience, the company is a trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, with a world known expertise within the Göttingen minipigs. The Company’s services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. Founded in 1977, Scantox is owned by Impilo, a leading Nordic healthcare investment company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231130940694/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom